We are live on ! Find out more
SCV

Sands Capital Ventures Portfolio holdings

AUM $614M
1-Year Est. Return 19.92%
This Fund
S&P 500
This Quarter Est. Return
+23.14%
1 Year Est. Return
+19.92%
3 Year Est. Return
+166.76%
5 Year Est. Return
+157.76%
10 Year Est. Return
–
AUM
$508M
AUM Growth
+$98.9M
Cap. Flow
+$13.2M
Cap. Flow %
2.6%
Top 10 Hldgs %
92.34%
Holding
20
New
–
Increased
10
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
IOT icon
Samsara
IOT
+$7.65M
2
BBNX
Beta Bionics
BBNX
+$6.6M
3
MNDY icon
monday.com
MNDY
+$2.35M
4
KVYO icon
Klaviyo
KVYO
+$2.27M
5
CPNG icon
Coupang
CPNG
+$142K

Top Sells

Rank Stock Value
1
PATH icon
UiPath
PATH
+$4.08M
2
TOST icon
Toast
TOST
+$2.12M

Sector Composition

Rank Sector Weight
1 Technology 37.55%
2 Consumer Discretionary 23.51%
3 Healthcare 19.55%
4 Financials 19.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KVYO icon
1
Klaviyo
KVYO
$5.26B
$118M 23.24%
3,515,065
+71,550
+2% +$2.27M
NU icon
2
Nu Holdings
NU
$73.6B
$98.4M 19.39%
7,175,434
+11,079
+0.2% +$133K
DASH icon
3
DoorDash
DASH
$94B
$94M 18.5%
381,202
+498
+0.1% +$99.9K
BBNX
4
Beta Bionics
BBNX
$790M
$52M 10.24%
3,570,113
+466,331
+15% +$6.6M
CPNG icon
5
Coupang
CPNG
$29B
$25.4M 5.01%
849,031
+5,555
+0.7% +$142K
IKT icon
6
Inhibikase Therapeutics
IKT
$336M
$21.4M 4.2%
10,950,000
– –
MNDY icon
7
monday.com
MNDY
$3.7B
$18.3M 3.61%
58,336
+8,428
+17% +$2.35M
IOT icon
8
Samsara
IOT
$23.2B
$17.4M 3.43%
438,485
+185,053
+73% +$7.65M
DDOG icon
9
Datadog
DDOG
$91.7B
$15.9M 3.14%
118,707
+777
+0.7% +$86K
CRWD icon
10
CrowdStrike
CRWD
$221B
$7.95M 1.57%
62,460
+220
+0.4% +$23.8K
TOST icon
11
Toast
TOST
$20.1B
$6.94M 1.37%
156,604
-54,007
-26% -$2.12M
TARS icon
12
Tarsus Pharmaceuticals
TARS
$3.04B
$6.89M 1.36%
170,000
– –
SNOW icon
13
Snowflake
SNOW
$114B
$6.04M 1.19%
27,005
+177
+0.7% +$32K
TXG icon
14
10x Genomics
TXG
$7.31B
$5.58M 1.1%
481,770
– –
ABOS icon
15
Acumen Pharmaceuticals
ABOS
$193M
$3.96M 0.78%
3,417,075
– –
BIOA
16
BioAge Labs
BIOA
$487M
$3.25M 0.64%
786,353
– –
ACRV icon
17
Acrivon Therapeutics
ACRV
$83.6M
$2.53M 0.5%
2,122,605
– –
CADL icon
18
Candel Therapeutics
CADL
$897M
$2.05M 0.4%
405,837
– –
TSHA icon
19
Taysha Gene Therapies
TSHA
$1.94B
$1.67M 0.33%
724,873
– –
PATH icon
20
UiPath
PATH
$8.3B
– –
-395,855
Closed -$4.08M

Similar funds

T2I
Turim 21 Investimentos Rio De Janeiro, Brazil $613M AUM 14.25% 1-Year Est. Return
VAG
VisionPoint Advisory Group Dallas, Texas $613M AUM 30.37% 1-Year Est. Return
MKA
M. Kulyk & Associates Decatur, Georgia $613M AUM 22.75% 1-Year Est. Return
CSIA
Conrad Siegel Investment Advisors Harrisburg, Pennsylvania $615M AUM 21.19% 1-Year Est. Return
ATFA
All Terrain Financial Advisors Coon Rapids, Minnesota $615M AUM 30.42% 1-Year Est. Return
AA
Aire Advisors Beverly Hills, California $615M AUM 25.07% 1-Year Est. Return
FWM
Fonville Wealth Management Richmond, Virginia $612M AUM 18.82% 1-Year Est. Return
FSA
Financial Security Advisor Virginia Beach, Virginia $615M AUM 26.08% 1-Year Est. Return

Sands Capital Ventures's Q2 2025 Portfolio in Review

As of Q2 2025, Sands Capital Ventures held 20 positions worth $508M, up 24% from $409M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Sands Capital Ventures's Q2 2025 filing shows 10 increased, 1 reduced and 1 closed positions. The largest sale was UiPath, an estimated $4.08M.

By sector, the portfolio is most concentrated in Technology at 38% of assets, down from 39% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Sands Capital Ventures added most to Samsara in Q2 2025, an estimated $7.65M increase.
  • Sands Capital Ventures's biggest Q2 2025 reduction was Toast, cutting an estimated $2.12M.
  • Sands Capital Ventures fully exited UiPath in Q2 2025, selling an estimated $4.08M.
  • Sands Capital Ventures's ten largest holdings make up 92% of its $508M portfolio in Q2 2025.
  • Sands Capital Ventures opened 0 new positions and closed 1 in Q2 2025.
  • Sands Capital Ventures's portfolio value rose 24% quarter-over-quarter to $508M.

Based on Sands Capital Ventures's 13F filing for Q2 2025, filed 13 Aug 2025.